Hepatitis B reactivation in occult viral carriers undergoing hematopoietic stem cell transplantation: A prospective study
Open Access
- 27 December 2016
- journal article
- research article
- Published by Wolters Kluwer Health in Hepatology
- Vol. 65 (5) , 1451-1461
Abstract
Hepatitis B virus (HBV) reactivation in hepatitis B surface antigen (HBsAg)–negative, antibody to hepatitis B core antigen (anti‐HBc)–positive patients after allogeneic hematopoietic stem cell transplantation (HSCT) has not been prospectively studied. HBsAg‐negative, anti‐HBc–positive patients with undetectable HBV DNA undergoing allogeneic HSCT were prospectively monitored every 4 weeks. The primary endpoint was HBV reactivation, defined as detectable HBV DNA (≥10 IU/mL). Secondary endpoints included overall survival, HBsAg positivity, and changes in liver biochemistry and antibody to HBsAg levels. Among 297 allogeneic HSCT recipients, 85 (28.7%) were HBsAg‐negative, anti‐HBc–positive, of whom 62 were recruited and monitored for a median of 48 (4‐104) weeks. The 2‐year cumulative HBV DNA detectability rate was 40.8%, occurring at a median of 44 (8‐100) weeks. Multivariate analysis showed that age ≥50 years (P = 0.004, hazard ratio = 8.2) and chronic graft‐versus‐host disease (P = 0.010, hazard ratio = 5.3) were significantly associated with HBV reactivation. Other clinical parameters, including baseline antibody to HBsAg status, serial changes in antibody to HBsAg levels, and donor serology, were not associated with HBV reactivation. Patients P = 0.004). Entecavir successfully suppressed HBV DNA to undetectable levels, with no cases developing biochemical hepatitis. Conclusion: HBsAg‐negative, anti‐HBc–positive patients had a high rate of HBV reactivation after allogeneic HSCT, with determinants of HBV reactivation including age ≥50 years and chronic graft‐versus‐host disease; treatment strategies based on these parameters may prevent HBV reactivation and subsequent complications. (ClinicalTrials.gov identifier NCT01481649.) (Hepatology 2017;65:1451‐1461).Keywords
Funding Information
- Health and Medical Research Fund (12111842)
This publication has 28 references indexed in Scilit:
- American Gastroenterological Association Institute Technical Review on Prevention and Treatment of Hepatitis B Virus Reactivation During Immunosuppressive Drug TherapyGastroenterology, 2015
- Hepatitis B Reactivation in Patients With Previous Hepatitis B Virus Exposure Undergoing Rituximab-Containing Chemotherapy for Lymphoma: A Prospective StudyJournal of Clinical Oncology, 2014
- Risk of hepatitis B surface antigen seroreversion after allogeneic hematopoietic SCTBone Marrow Transplantation, 2010
- Hepatitis B Virus Reactivation following Allogeneic Hematopoietic Stem Cell TransplantationTransplantation and Cellular Therapy, 2009
- HBsAg Seroclearance in Chronic Hepatitis B in Asian Patients: Replicative Level and Risk of Hepatocellular CarcinomaGastroenterology, 2008
- Systematic Review: The Effect of Preventive Lamivudine on Hepatitis B Reactivation during ChemotherapyAnnals of Internal Medicine, 2008
- Occult hepatitis B virus infectionJournal of Hepatology, 2007
- Hepatitis B Virus Reactivation After Cytotoxic Chemotherapy: The Disease and Its PreventionClinical Gastroenterology and Hepatology, 2006
- Reactivation of Hepatitis B Infection following Allogeneic Bone Marrow Transplantation in a Hepatitis B-Immune Patient: Case Report and Review of the LiteratureClinical Infectious Diseases, 2005
- Occult hepatitis B virus after acute self-limited infection persisting for 30 years without sequence variationJournal of Hepatology, 2000